Form 4: Bain Capital Life Sciences Entities Acquire Pre-Funded Warrants in NewAmsterdam Pharma

Bain Capital Life Sciences entities have acquired pre-funded warrants to purchase over 1.6 million ordinary shares of NewAmsterdam Pharma Co N.V.

Summary

• Bain Capital Life Sciences Investors, LLC and related entities have filed a Form 4 disclosing the acquisition of pre-funded warrants.
• These warrants allow the purchase of 1,632,653 ordinary shares of NewAmsterdam Pharma Co N.V.
• The warrants were acquired on December 13, 2024, at a price of $0.0001 per warrant.
• The exercise price of the warrants is $24.4999 per share.
• The warrants were acquired through an underwritten public offering.
• The warrants do not expire and are subject to a 9.99% ownership limitation.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, but the continued investment by Bain Capital Life Sciences is a positive sign. The sentiment is neutral to slightly positive.

Positives

• The acquisition of warrants by Bain Capital Life Sciences indicates a continued investment in NewAmsterdam Pharma.
• The warrants do not expire, providing flexibility for Bain Capital Life Sciences.

Risks

• The 9.99% ownership limitation on the warrants could restrict Bain Capital Life Sciences' ability to increase its stake in the company.
• The exercise of the warrants is dependent on the market price of the ordinary shares.

Future Outlook

The document does not contain any specific forward-looking statements, but the acquisition of warrants suggests a continued interest in the company by Bain Capital Life Sciences.

Industry Context

This filing is a standard disclosure of changes in beneficial ownership, common in the pharmaceutical and biotech industries where institutional investors often hold significant stakes.

Comparison to Industry Standards

• The acquisition of pre-funded warrants is a common method for institutional investors to gain exposure to a company's equity.
• Similar transactions can be seen with other biotech companies such as Alnylam Pharmaceuticals and Moderna, where large investment firms have acquired warrants or options.
• The 9.99% ownership limitation is also a common clause to avoid triggering certain regulatory thresholds.

Stakeholder Impact

• Shareholders may view the acquisition of warrants by Bain Capital Life Sciences as a positive sign of confidence in the company.
• The potential exercise of warrants could lead to dilution of existing shares.

Next Steps

• Bain Capital Life Sciences may exercise the warrants in the future, depending on market conditions and their investment strategy.
• NewAmsterdam Pharma may see an increase in its share price if the warrants are exercised.

Key Dates

Keywords

pre-funded warrants, Bain Capital Life Sciences, NewAmsterdam Pharma, ordinary shares, public offering, beneficial ownership, Form 4